Copy number signatures and mutational processes in ovarian carcinoma.
Authors
Macintyre, GGoranova, T
De Silva, D
Ennis, D
Piskorz, A
Eldridge, M
Sie, D
Lewsley, L
Hanif, A
Wilson, C
Dowson, S
Glasspool, R
Lockley, M
Brockbank, E
Montes, A
Walther, A
Sundar, S
Edmondson, R
Hall, G
Clamp, Andrew R
Gourley, C
Hall, M
Fotopoulou, C
Gabra, H
Paul, J
Supernat, A
Millan, D
Hoyle, A
Bryson, G
Nourse, C
Mincarelli, L
Sanchez, L
Ylstra, B
Jimenez-Linan, M
Moore, L
Hofmann, O
Markowetz, F
McNeish, I
Brenton, J
Affiliation
Cancer Research UK Cambridge Institute, Cambridge, UKIssue Date
2018-09
Metadata
Show full item recordAbstract
The genomic complexity of profound copy number aberrations has prevented effective molecular stratification of ovarian cancers. Here, to decode this complexity, we derived copy number signatures from shallow whole-genome sequencing of 117 high-grade serous ovarian cancer (HGSOC) cases, which were validated on 527 independent cases. We show that HGSOC comprises a continuum of genomes shaped by multiple mutational processes that result in known patterns of genomic aberration. Copy number signature exposures at diagnosis predict both overall survival and the probability of platinum-resistant relapse. Measurement of signature exposures provides a rational framework to choose combination treatments that target multiple mutational processes.Citation
Copy number signatures and mutational processes in ovarian carcinoma. 2018, 50(9): 1262-1270 Nat GenetJournal
Nature GeneticsDOI
10.1038/s41588-018-0179-8PubMed ID
30104763Type
ArticleLanguage
enISSN
1546-1718ae974a485f413a2113503eed53cd6c53
10.1038/s41588-018-0179-8
Scopus Count
Collections
Related articles
- The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma.
- Authors: Smith P, Bradley T, Gavarró LM, Goranova T, Ennis DP, Mirza HB, De Silva D, Piskorz AM, Sauer CM, Al-Khalidi S, Funingana IG, Reinius MAV, Giannone G, Lewsley LA, Stobo J, McQueen J, Bryson G, Eldridge M, BriTROC Investigators, Macintyre G, Markowetz F, Brenton JD, McNeish IA
- Issue date: 2023 Jul 20
- Focal Recurrent Copy Number Alterations Characterize Disease Relapse in High Grade Serous Ovarian Cancer Patients with Good Clinical Prognosis: A Pilot Study.
- Authors: Dugo M, Devecchi A, De Cecco L, Cecchin E, Mezzanzanica D, Sensi M, Bagnoli M
- Issue date: 2019 Sep 5
- Abnormal plasma DNA profiles in early ovarian cancer using a non-invasive prenatal testing platform: implications for cancer screening.
- Authors: Cohen PA, Flowers N, Tong S, Hannan N, Pertile MD, Hui L
- Issue date: 2016 Aug 24
- High-grade serous ovarian carcinoma organoids as models of chromosomal instability.
- Authors: Vias M, Morrill Gavarró L, Sauer CM, Sanders DA, Piskorz AM, Couturier DL, Ballereau S, Hernando B, Schneider MP, Hall J, Correia-Martins F, Markowetz F, Macintyre G, Brenton JD
- Issue date: 2023 May 11
- A BRCA1/2 Mutational Signature and Survival in Ovarian High-Grade Serous Carcinoma.
- Authors: Dong F, Davineni PK, Howitt BE, Beck AH
- Issue date: 2016 Nov